Zobrazeno 1 - 10
of 113
pro vyhledávání: '"Arthur Kavanaugh"'
Autor:
Mark C. Genovese, Y. Tan, L. Meuleners, Maria Greenwald, Rieke Alten, Mykola Stanislavchuk, Susan J. Lee, R. Besuyen, Rene Westhovens, Di An, John S. Sundy, Arthur Kavanaugh, Lei Ye, Alberto Spindler, Kevin L. Winthrop
Publikováno v:
The Journal of Rheumatology. 48:1230-1238
ObjectiveThe long-term safety and efficacy of filgotinib (from phase II studies), with or without methotrexate (MTX), for the treatment of patients with rheumatoid arthritis was assessed in DARWIN 3, a long-term, open-label extension study (ClinicalT
Autor:
Melania Martínez-Morillo, Rekha Narasimhan, L. Mateo, Brian Pedersen, Monica Guma, Anahy Brandy, Arthur Kavanaugh, Roxana Coras, Aaron M. Armando, Águeda Prior-Español, Mohit Jain, Oswald Quehenberger
Publikováno v:
J Gerontol A Biol Sci Med Sci
Elderly-onset rheumatoid arthritis (EORA) and polymyalgia rheumatica (PMR) are common rheumatic diseases in older adults. Oxylipins are bioactive lipids derived from omega-6 (n-6) and omega-3 (n-3) polyunsaturated fatty acids (PUFAs) that serve as ac
Autor:
Tore K Kvien, Marc de Longueville, Niels Vande Casteele, Hubert Marotte, Arthur Kavanaugh, Stéphane Paul, Philippe Goupille, William J. Sandborn, Denis Mulleman
Publikováno v:
Clinical and Translational Science, Vol 13, Iss 4, Pp 743-751 (2020)
Clinical and Translational Science
Clinical and Translational Science
Anti‐tumor necrosis factor (anti‐TNF) drugs are often prescribed for the treatment of rheumatoid arthritis (RA) and other immune‐mediated inflammatory diseases. Although this treatment has been shown to be effective in many patients, up to 40%
Autor:
M. Elaine Husni, Atul Deodhar, Sergio Schwartzman, Soumya D. Chakravarty, Elizabeth C. Hsia, Jocelyn H. Leu, Yiying Zhou, Kim H. Lo, Arthur Kavanaugh
Publikováno v:
Arthritis researchtherapy. 24(1)
Background Intravenous (IV) golimumab, a TNFi, is approved for treating rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). We analyzed pooled safety results from three phase 3 IV golimumab trials in these rheumatol
Publikováno v:
Modern rheumatology. 32(1)
In the treatment of rheumatoid arthritis (RA), Janus kinase inhibitors (jakinibs) represent an emerging class of targeted therapies in addition to biologics. The number of jakinibs has been growing and as of 2020, filgotinib was the latest jakinib to
Autor:
Michaela, Koehm, Matthew J, McIntosh, Michael W, Hofmann, Varghese, Abraham, Cem, Gabay, Ernest H, Choy, Arthur, Kavanaugh, Harald, Burkhardt, Frank, Behrens
Publikováno v:
Rheumatology international. 40(5)
Assessment of individual therapeutic responses provides valuable information concerning treatment benefits in individual patients. We evaluated individual therapeutic responses as determined by the Disease Activity Score-28 joints critical difference
Autor:
Arthur Kavanaugh, Carol J. Etzel, Jenny Griffith, Joel M. Kremer, Jeff Greenberg, Rakesh K. Singh, C. Karki
Publikováno v:
Clinical rheumatology, vol 37, iss 8
Clinical Rheumatology
Clinical Rheumatology
To compare disease burden and biologic use among psoriatic arthritis (PsA) or rheumatoid arthritis (RA) patients recruited to the Corrona registry. Retrospective study of patients with PsA or RA enrolled in Corrona between January 2002 and March 2013
Autor:
Jenny Griffith, Arthur Kavanaugh, Jeff Greenberg, George W. Reed, Alan Friedman, Katherine C. Saunders, Arijit Ganguli, Edward C. Keystone
Publikováno v:
Rheumatology. 56:1095-1101
To compare clinical outcomes and treatment patterns among patients with moderate vs severe RA following biologic DMARD initiation.Biologics-naive patients with moderate to severe RA [Clinical Disease Activity Index (CDAI)10] who initiated a biologic
Autor:
Hendrik Schulze-Koops, Marco Matucci-Cerinic, Goran Babic, Philip Young, Yannick Allanore, Arthur Kavanaugh, Janusz Jaworski, Eugeniusz J. Kucharz, Maya H Buch
Publikováno v:
Arthritis Research & Therapy, Vol 21, Iss 1, Pp 1-8 (2019)
Arthritis Research & Therapy
Jaworski, J, Matucci-Cerinic, M, Schulze-Koops, H, Buch, M H, Kucharz, E J, Allanore, Y, Kavanaugh, A, Young, P & Babic, G 2019, ' Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis : 48-week results from the phase III, randomized, double-blind EQUIRA study ', Arthritis Research & Therapy, vol. 21, no. 1, pp. 130 . https://doi.org/10.1186/s13075-019-1907-x
Arthritis Research & Therapy
Jaworski, J, Matucci-Cerinic, M, Schulze-Koops, H, Buch, M H, Kucharz, E J, Allanore, Y, Kavanaugh, A, Young, P & Babic, G 2019, ' Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis : 48-week results from the phase III, randomized, double-blind EQUIRA study ', Arthritis Research & Therapy, vol. 21, no. 1, pp. 130 . https://doi.org/10.1186/s13075-019-1907-x
Background Sandoz etanercept (SDZ ETN; GP2015) is an etanercept biosimilar with equivalent efficacy and comparable safety and immunogenicity to reference etanercept (ETN) in patients with moderate-to-severe chronic plaque-type psoriasis. Methods EQUI
Autor:
Alla, Skapenko, Josef S, Smolen, Arthur, Kavanaugh, Vipin, Arora, Hartmut, Kupper, Hendrik, Schulze-Koops
Publikováno v:
Clinical and experimental rheumatology. 37(5)
Biologics, including tumour necrosis factor inhibitors such as adalimumab (ADA), have significantly improved outcomes in rheumatoid arthritis (RA). Because the clinical course of RA and response to therapy may be influenced by the genetic background